Acrux Radiopharma Consulting and Tema Sinergie enter a strategic partnership to provide dedicated products and solutions for the nuclear medicine market in Chile

16 May 2023

During the last decade Acrux Radiopharma Consulting have witnessed an outstanding growth of the nuclear medicine market in Chile and Latin-America. The advent of new radiopharmaceuticals for imaging and therapy of certain types of cancer, the increased availability of PET/CT technology in the region, and new regulations require dedicated solutions for radiation protection, dispensing and environmental monitoring.

As part of this strategic partnership, Acrux Radiopharma Consulting will provide technical services including installations, qualifications, training, maintenance, and process development for Tema Sinergie and their customers in Latin America. Acrux will further act as local representative in Chile and Tema Sinergie‘s products. Acrux provides a team of experts, trained to conduct preventive maintenance, installation, and operation qualifications and with over 15 years of hands-on experience with products from Tema Sinergie in radiopharmaceutical production.

We are confindent that this partnership will offer a more efficient sales service and a quick and timely after-sales assistance to both the existing and new customers of the area.


Discover more about Acrux Radiopharma Consulting

For details

Posted in Nuclear Medicine
C.F., P.IVA, VATn. IT00970310397
Business Register of Ravenna n. 00970310397  |  R.E.A. 111877
RAEE IT08020000002755
Capital Stock € 2.000.000,00 paid-up